| Date | Title | | | 12/21/10 | Landmark Medtronic CoreValve(R) U.S. Clinical Trial Begins| Investigational Therapy Offers Treatment Alternative to Open
Heart-Surgery for Patients with Severe Aortic Stenosis
MINNEAPOLIS, Dec 21, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the beginning of its
Medtronic CoreValve(R) U.S. Pivotal clinical trial in the United States.
The first CoreValve transcatheter aortic valve implantation (TAVI)
procedure was performed by David H. Adams, M.D., and Samin K. Sharma,
M.D., at The Mount Sin... |
|  | | 12/21/10 | Med-Tech Advance for 'Silent Killer': FDA Approves
Medtronic Device to Fix Abdominal Aortic Aneurysms| Endurant(R) AAA Stent Graft Expands Patient
Access to Minimally Invasive Procedure To Repair Dangerous Bulge in
Body's Main Artery Without Major Surgery
MINNEAPOLIS, Dec 21, 2010 (BUSINESS WIRE) --An estimated 1.2 million people in the United States have an abdominal
aortic aneurysm (AAA) - a dangerous bulge or ballooning in their bodies'
main artery1 that typically causes no symptoms until it
ruptures, which can be deadly - and most of them don't know ... |
| | | 12/20/10 | Medtronic Announces Chairman and CEO William A. Hawkins to Retire at
End of Company's Current Fiscal Year| MINNEAPOLIS, Dec 20, 2010 (BUSINESS WIRE) --Medtronic (NYSE:MDT) announced today that William A. Hawkins intends to
retire as Chairman and CEO of Medtronic at the conclusion of the current
fiscal year ending April 29, 2011. The company's board of directors has
initiated an external search for his replacement, and Mr. Hawkins plans
to remain until his successor is appointed.
"Bill has made a very significant impact at Medtronic and his service is
deepl... |
| | | 12/17/10 | Medtronic Receives FDA Approval for First and Only Cryoballoon
Ablation Treatment in the U.S. for Paroxysmal Atrial Fibrillation| New Arctic Front(R) Cardiac CryoAblation
Catheter System Reduces Symptoms for Patients with Common Heart Rhythm
Disorder
MINNEAPOLIS, Dec 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug
Administration (FDA) has approved its Arctic Front(R) Cardiac
CryoAblation Catheter system, the first and only Cryoballoon in the
United States indicated for the treatment of drug refractory paroxysmal
atrial fibr... |
| | | 12/09/10 | Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year
2011| MINNEAPOLIS, Dec 09, 2010 (BUSINESS WIRE) --The board of directors of Medtronic, Inc. (NYSE:MDT), today approved a
cash dividend of $0.225 per share of the company's common stock. The
dividend is payable on January 28, 2011, to shareholders of record at
the close of business on January 7, 2011.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
- alleviating pain, restoring he... |
| | | 12/09/10 | Medtronic CoreValve(R) System Gains CE Mark for New Subclavian Approach
to Transcatheter Aortic Valve Implantation| Approval is Expected to Expand Access to Care for Patients with
Severe Aortic Stenosis
MINNEAPOLIS, Dec 09, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) has received CE (Conformité Européenne) Mark
for the Medtronic CoreValve(R) System to be delivered through a
novel approach, which would allow access through the subclavian artery
located beneath the collar bone. As a result, thousands more patients in
Europe with severe aortic stenosis may be eli... |
| | | 12/02/10 | European Economic Analysis Shows Cost Benefit of Cardiac
Resynchronization Therapy in Mild Heart Failure Patients| New Findings from Sub-Analysis of REVERSE Trial Published in the
European Heart Journal
MINNEAPOLIS, Dec 02, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced findings from an economic
sub-study of the REVERSE (Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction) trial published in the European
Heart Journal demonstrating for the first time that cardiac
resynchronization therapy (CRT) is cost-effective in mildly sym... |
| | | 12/02/10 | Medtronic Announces CD HORIZON(R) System 510k
Pedicle Screw Clearance for Adolescent Idiopathic Scoliosis| New Indication Will Help Advance Spine Care and Research for Children
MEMPHIS, Tenn., Dec 02, 2010 (BUSINESS WIRE) --Medtronic (NYSE: MDT) announced today it received clearance to treat
adolescent idiopathic scoliosis (AIS). This marks the first such
clearance by the FDA under the Agency's newly established category for
pediatric AIS patients treated with posterior pedicle screw
instrumentation.
AIS is the most common type of scoliosis seen in children and... |
| | | 11/23/10 | Medtronic Reports Second Quarter Earnings|
International Revenue of $1.6 Billion Grew 6% on a Constant
Currency Basis; 4% As Reported
Emerging Market Revenue Grew 19% on Constant Currency Basis; 22% As
Reported
Non-GAAP Diluted EPS of $0.82 Grew 6%; GAAP Diluted EPS of $0.52
Declined 33%
MINNEAPOLIS, Nov 23, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced financial results for its
second quarter of fiscal year 2011, which ended October 29, 2010... |
| | | 11/22/10 | Medtronic Signs Agreement to Acquire Ardian| MINNEAPOLIS & MOUNTAIN VIEW, Calif., Nov 22, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) and privately-held Ardian, Inc. announced
today that they have entered into a merger agreement whereby Medtronic
will acquire Ardian. The agreement calls for Medtronic to make an up
front cash payment of $800 million, plus commercial milestones equal to
the annual revenue growth through the end of Medtronic's fiscal year
2015. Medtronic had previously invest... |
| | | 11/19/10 | Medtronic Presents 30-Day Data on Valiant(R)
Thoracic Stent Graft| Initial Results from U.S. IDE Study Demonstrate Early Safety and
Effectiveness of Implantable Medical Device for Minimally Invasive
Treatment of Thoracic Aortic Aneurysms
MINNEAPOLIS & NEW YORK, Nov 19, 2010 (BUSINESS WIRE) --An implantable medical device used in the minimally invasive treatment
of thoracic aortic aneurysms,the Valiant(R) Thoracic
Stent Graft System from Medtronic, Inc. (NYSE: MDT), delivered strong
results through 30 days of patien... |
| | | 11/19/10 | Medtronic Presents One-Year Data on Endurant(R)
Stent Graft| Definitive Results from U.S. IDE Study Demonstrate Durable Safety and
Effectiveness of Implantable Medical Device for Minimally Invasive
Treatment of Abdominal Aortic Aneurysms
MINNEAPOLIS & NEW YORK, Nov 19, 2010 (BUSINESS WIRE) --An implantable medical device used in the minimally invasive treatment
of abdominal aortic aneurysms, the Endurant(R) Stent Graft
System from Medtronic, Inc. (NYSE: MDT), delivered strong results
through one year of patie... |
| | | 11/19/10 | Medtronic's Reveal(R) Insertable Cardiac
Monitor Led to Effective Diagnosis and Specific Treatment for Patients
with Unexplained Fainting| PICTURE Registry Results Published Online Today in EP-Europace
MINNEAPOLIS, Nov 19, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced the publication of data
showing that use of its Reveal(R) family of Insertable Cardiac
Monitors led to diagnosis and specific treatment for 78 percent (170 of
218) of patients who experienced a recurrent syncopal (fainting) event
during the course of the study. Of those diagnosed patients, 75 percent
were ... |
| | | 11/18/10 | Medtronic Introduces New Spinal Cord Stimulation Multi-Lead Trialing
Cable for Enhanced Patient Screening Test| MINNEAPOLIS, Nov 18, 2010 (BUSINESS WIRE) --Medtronic Inc. (NYSE: MDT), the leader in spinal cord stimulation for
more than 25 years, today announced U.S. Food and Drug Administration
(FDA) clearance and the global launch of the Multi-Lead Trialing Cable
for use in the patient screening test for Medtronic spinal cord
stimulation (SCS) therapy. Introduced this month in the United States,
Europe and Canada, the streamlined trialing system allows physicians t... |
| | | 11/18/10 | Medtronic Announces Global Launch of New Heart Valve Repair Ring| Tricuspid Annuloplasty Ring is Designed to Adapt to the Heart's
Natural Tricuspid Valve
Acquired Through ATS Medical, New Ring Enhances Medtronic's Surgical
Heart Valve Repair Portfolio
MINNEAPOLIS, Nov 18, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the global launch and first
clinical use of the Tri-Ad(TM) Semi-Flexible Tricuspid
Annuloplasty Ring for the treatment of tricuspid valve disease. The ring
is designed to adapt to th... |
| | | 11/17/10 | Medtronic Unveils EVARpro(R) Suite of Services
to Streamline Clinical Use of Aortic Stent Grafts| New Offering Improves Pre-Case Planning, Procedural Efficiency and
Patient Follow-Up
MINNEAPOLIS, Nov 17, 2010 (BUSINESS WIRE) --Improving the efficiency of endovascular aortic repair (EVAR),
Medtronic, Inc. (NYSE: MDT), today introduced EVARpro(R), a
suite of value-added services for physicians who specialize in the
minimally invasive treatment of aortic aneurysms and injuries with the
company's stent grafts.
Available exclusively to Medtronic cus... |
| | | 11/16/10 | Medtronic Completes Acquisition of Osteotech| Acquisition Expands Product Offering and Pipeline for Biologics
Business
MEMPHIS, Tenn., Nov 16, 2010 (BUSINESS WIRE) --Moving to expand its Biologics product offerings, Medtronic, Inc. (NYSE:
MDT), announced today it has completed the acquisition of Osteotech,
following payment of $6.50 per share in cash for each share of Osteotech
stock, with a total transaction value of approximately $123 million.
Osteotech is a leader in the growing field of biologic p... |
| | | 11/15/10 | Physio-Control and AirStrip Technologies Announce Partnership to
Deliver Integrated Mobile Solutions| Innovative applications will allow clinicians to interact with
patient ECG data in new ways
SAN ANTONIO & REDMOND, Wash., Nov 15, 2010 (BUSINESS WIRE) --Innovative new mobile cardiac monitoring solutions are on the horizon.
At the American Heart Association Scientific Sessions 2010, AirStrip
Technologies, a pioneer in mobile medical software applications and
Physio-Control, Inc., the world leader in emergency medical solutions,
announced a joint par... |
| | | 11/15/10 | Physio-Control Introduces Next Generation of LIFENET System| New Features Offer Clinical and Operational Efficiencies for EMS and
Hospital Teams
REDMOND, Wash., Nov 15, 2010 (BUSINESS WIRE) --Physio-Control, Inc., a wholly-owned subsidiary of Medtronic, Inc.,
(NYSE: MDT), announced today it has received 510(k) clearance from the
U.S. Food and Drug Administration (FDA) to market LIFENET System 5.0
within the United States. LIFENET 5.0 is the latest version of
Physio-Control's web-based data network, providing emer... |
| | | 11/15/10 | Medtronic Launches European Web Portal to Stimulate Medical
Technology Innovation| Medtronic Eureka seeks partnership with innovating physicians to
improve healthcare
TOLOCHENAZ, Switzerland, Nov 15, 2010 (BUSINESS WIRE) --Medtronic today launched Medtronic Eureka, a European web-based portal
for medical technology innovation designed to help physicians and
medical technology inventors to bring their innovative ideas to life.
The Medtronic Eureka program (www.MedtronicEUreka.com)
is designed to provide a streamlined, single entry point f... |
| | | 11/14/10 | Landmark Medtronic-Supported Study Shows CRT-D Reduced Mortality by
29 Percent in Mildly Symptomatic Heart Failure Patients| RAFT Clinical Trial First to Show Significantly Reduced Mortality in
Mildly Symptomatic Patients
Study Has Longest Follow-Up and Largest Patient Months of Experience
of Any CRT Therapy Study
MINNEAPOLIS & CHICAGO, Nov 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced that the landmark RAFT
(Resynchronization/Defibrillation for Ambulatory Heart Failure Trial)
clinical trial shows Medtronic cardiac resynchronization
therapy-defib... |
| | | 11/12/10 | Medtronic to Announce Financial Results for the Second Quarter of
Fiscal Year 2011| MINNEAPOLIS, Nov 12, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced today it will report financial
results for the second quarter of its fiscal year 2011 on Tuesday,
November 23, 2010. A news release will be issued at approximately 6:15
a.m. Central Time and will be available at www.medtronic.com/newsroom.
The earnings news release will include summary financial information for
Medtronic's second quarter ended October 29, 2010.
Medtronic... |
| | | 11/04/10 | Medtronic Marks Bladder Health Awareness Month with National Women's
Health Campaign| Educational Campaign Encourages Women to Seek Support for Bladder
Control Issues
MINNEAPOLIS, Nov 04, 2010 (BUSINESS WIRE) --In support of Bladder Health Awareness Month and the struggles 33
million Americans face year-round with bladder control issues,
Medtronic, Inc. (NYSE: MDT) is extending its national women's health
campaign, Facing Our Moments Together(TM). The campaign, conducted
in partnership with leading patient advocacy groups, is designed to... |
| | | 11/01/10 | Medtronic Receives FDA Approval of Talent Captivia(R) System
for Endovascular Treatment of Thoracic Aortic Aneurysms| New Tip Capture Feature Enables Controlled Deployment and Precise
Placement of Stent Graft During Minimally Invasive Procedure to Repair
Body's Main Artery
MINNEAPOLIS, Nov 01, 2010 (BUSINESS WIRE) --Advancing the minimally invasive treatment of aortic aneurysms,
Medtronic, Inc. (NYSE: MDT), today announced approval by the U.S. Food
and Drug Administration (FDA) of the Talent Thoracic Stent Graft with
Captivia(R) Delivery System, which features a tip
... |
| | | 10/29/10 | FDA Classifies Previous Field Action of Medtronic Surgical Device as
Class I Recall| MINNEAPOLIS, Oct 29, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the U.S. Food and Drug
Administration (FDA) has classified the company's previous action
related to the Octopus(R) Nuvo Tissue Stabilizer as a Class I
recall. FDA classifies a recall as Class I when the agency believes that
there is a reasonable probability that use of the recalled product will
cause serious adverse health consequences or death. On Sept. 14, 2010,
... |
| | | 10/21/10 | Medtronic Announces New Inflatable Bone Tamp for Treatment of
Vertebral Compression Fractures| Kyphon Xpander(TM) II Inflatable Bone Tamp Is Latest Innovation in
Minimally Invasive Treatment of Spinal Fractures
MINNEAPOLIS, Oct 21, 2010 (BUSINESS WIRE) --Medtronic Inc. (NYSE:MDT) today announced Food and Drug Administration
(FDA) clearance of the Kyphon Xpander II Inflatable Bone Tamp (IBT) for
the treatment of vertebral compression fractures with minimally invasive
Kyphon(R) Balloon Kyphoplasty.
Kyphon Xpander II is the latest innovation from the c... |
| | | 10/15/10 | Medtronic Clinical Trial Receives FDA Approval to Evaluate New
CoreValve(R) System for Aortic Valve Implantation| Investigational Transcatheter Aortic Valve Implantation System Part
of Medtronic's Growing Portfolio for U.S. Patients with Severe Aortic
Stenosis
MINNEAPOLIS, Oct 15, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug
Administration (FDA) conditional approval for its Investigational Device
Exemption (IDE) application and pivotal clinical trial protocol to begin
evaluating the Medtronic CoreValve System for transcathet... |
| | | 10/14/10 | Medtronic Settles US Lawsuits on Sprint Fidelis Family of
Defibrillation Leads| MINNEAPOLIS, Oct 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced that it has entered into an
agreement to settle existing U.S. lawsuits relating to its Sprint Fidelis(R)
family of defibrillation leads (Sprint Fidelis Models: 6930, 6931, 6948,
6949) that were the subject of a field action announced on October 15,
2007.
Under the terms of the agreement, Medtronic has agreed, subject to
certain conditions, to settle U.S. lawsuits an... |
| | | 10/13/10 | American Bone Health, Medtronic and San Francisco Area Hospitals Join
Forces to Raise Awareness of Spinal Fractures| First-Ever Spinal Fracture Awareness Walk and Health Fair Set for
Nov. 14, 2010
SAN FRANCISCO, Oct 13, 2010 (BUSINESS WIRE) --To increase awareness of the debilitating effects of spinal fractures
and the symptoms, causes and available treatments, American Bone Health;
Medtronic, Inc. (NYSE:MDT); UCSF Medical Center; and Spinal Diagnostics
and Treatment Center have joined forces to host the first-ever Walk Tall
For Life Spinal Fracture Awareness Walk and... |
| | | 10/06/10 | Medtronic Introduces the VERTEX SELECT(R)
Reconstruction System Posted Screw Module| MEMPHIS, Tenn., Oct 06, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced the U.S. launch of the VERTEX
SELECT(R) Reconstruction System Posted Screw Module. The
announcement was made at the 25th Annual Meeting of the North American
Spine Society (NASS) in Orlando, Fla.
The Posted Screw Module is a supplement to the VERTEX SELECT(R)
Reconstruction System and broadens surgeons' options for treating
patients who require fixation of the ve... |
| | | 10/05/10 | Medtronic Announces New Curette for Treatment of Vertebral
Compression Fractures| MINNEAPOLIS, Oct 05, 2010 (BUSINESS WIRE) --Medtronic Inc. (NYSE:MDT) today announced the launch of the new KYPHON(R)
Express(TM) Curette for scraping or scoring bone in the spine, including
during treatment of vertebral compression fractures with minimally
invasive KYPHON(R) Balloon Kyphoplasty.
The Kyphon Products Division of Medtronic Spinal and Biologics will
showcase the new curette, along with the recently launched KYPHON(R)
Cement Delivery Syst... |
| | | 10/05/10 | 2010 Medtronic Twin Cities Marathon "Global Heroes" Celebrate
Accomplishment| Extraordinary Runners from Around the World Complete Medtronic Twin
Cities Marathon Events with Help from Medical Technology
MINNEAPOLIS, Oct 05, 2010 (BUSINESS WIRE) --Twenty-four Medtronic Global Heroes, long-distance runners who benefit
from medical technology, successfully completed either the Medtronic
Twin Cities Marathon or the Medtronic TC 10 Mile on Sunday, Oct. 3.
These extraordinary runners hail from the United States and nine other
countries, i... |
| | | 10/01/10 | Medtronic Extends Sponsorship of Medtronic Twin Cities Marathon| MINNEAPOLIS, Oct 01, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) and Twin Cities In Motion (formerly Twin
Cities Marathon, Inc.) announced they have signed a letter of intent to
continue their partnership at this morning's pre-race press conference.
Medtronic will remain title sponsor for at least three additional years
for four key Twin Cities In Motion events: TC 1 Mile, TC Family Events,
TC 10 Mile, and the Twin Cities Marathon. Additionally, the... |
| | | 09/28/10 | Medtronic Advances Research on Drug-Eluting Balloons for Coronary and
Peripheral Artery Disease| Data from 1,500-Patient IN.PACT(TM) Clinical Program
Presented at TCT;
First Patient Enrolled in European Study on Device's Use in SFA
Disease
WASHINGTON, Sep 28, 2010 (BUSINESS WIRE) --Advancing research on drug-eluting balloons for the treatment of
coronary and peripheral artery disease, Medtronic, Inc. (NYSE: MDT),
today announced the latest results from the IN.PACT drug-eluting balloon
(DEB) clinical program presented last week at the Transcatheter... |
| | | 09/28/10 | Medtronic's Insertable Cardiac Monitor Documented Arrhythmias in
Post-Heart Attack Patients| Reveal(R) Plus Study Results Published Today in
Circulation
MINNEAPOLIS, Sep 28, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced the publication of results
from a multicenter, prospective study that demonstrated that the
company's Reveal(R) Plus implantable cardiac monitor recorded
arrhythmias in 46 percent of patients with ejection fractions1
less than or equal to 40 percent and who had previously suffered an
acute myocardial ... |
| | | 09/23/10 | Medtronic Initiates Global Commitment to Address Burden of
Non-Communicable Disease| Announced at Clinton Global Initiative, an initial $1 million in
grants are part of an overall strategic effort to reduce the burden of
chronic disease
MINNEAPOLIS, Sep 23, 2010 (BUSINESS WIRE) --Medtronic, Inc. today announced at the Clinton Global Initiative a $1
million commitment to the NCD Alliance. The grants are made in
preparation for the United Nations Summit on non-communicable diseases
(NCD) occurring in September 2011, and part of a comprehe... |
| | | 09/22/10 | Medtronic's Resolute Drug-Eluting Stent Shows Strong Performance in
Second 'All Comers' Study| Consistent Results in More Than 3,600 Patients from Complex Daily
Practice of Interventional Cardiology Strengthen Evidence on Implantable
Heart Device
WASHINGTON, Sep 22, 2010 (BUSINESS WIRE) --Coronary artery disease, a leading cause of death and poor quality of
life worldwide, runs the gamut from simple to complex, which complicates
the daily practice of interventional cardiology. New clinical data from
a second, large international study that enroll... |
| | | 09/20/10 | Medtronic Receives FDA Approval of Integrity(R)
Coronary Stent| Superior Deliverability Distinguishes New Medical Device Based on
Engineering Advance of Continuous Sinusoid Technology
MINNEAPOLIS, Sep 20, 2010 (BUSINESS WIRE) --Delivering another innovation for interventional cardiology, Medtronic,
Inc. (NYSE: MDT), announced today the U.S. Food and Drug Administration
(FDA) approval of the Integrity Coronary Stent System. The new platform
for Medtronic's coronary stents, including the Integrity bare-metal
stent, ... |
| | | 09/17/10 | Medtronic Showcases Cardiovascular Devices at TCT 2010| Interventional Cardiology Meeting Features New Data on Resolute(R)
Drug-Eluting Stent, IN.PACT(TM) Line of
Drug-Eluting Balloons and CoreValve(R)
Transcatheter Aortic Valve
MINNEAPOLIS, Sep 17, 2010 (BUSINESS WIRE) --Representing the broadest range of medical technology for the
interventional treatment of cardiovascular disease,Medtronic,
Inc. (NYSE: MDT), today announced its schedule of events for
Transcatheter Cardiovascular Therapeutics (TCT)... |
| | | 09/17/10 | Newly Published Data Show Occipital Nerve Stimulation May Be a
Promising New Therapy for Chronic Migraine| Initial Results Suggest ONS Warrants Further Study for Control of
Chronic Migraine
MINNEAPOLIS, Sep 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced that data from a multicenter,
prospective, randomized, blinded, feasibility trial published today show
promise for occipital nerve stimulation (ONS) for treating medically
refractory chronic migraines and support the need for further controlled
study of the treatment. The study, called Occip... |
| | | 09/16/10 | Medtronic Receives European CE Mark Approval for Deep Brain
Stimulation Therapy for Refractory Epilepsy| Further Clinical Study Required for Application to U.S. Food and
Drug Administration
MINNEAPOLIS, Sep 16, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced that the company has
received CE (Conformité Européenne) Mark approval for Medtronic
Deep Brain Stimulation (DBS) Therapy in Europe as adjunctive treatment
for partial-onset seizures in adults with medically refractory epilepsy.
DBS therapy for epilepsy delivers controlled electrical... |
| | | 09/14/10 | Medtronic CFO Gary Ellis to Speak at UBS Global Life Sciences
Conference| MINNEAPOLIS, Sep 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology
company, today announced it will participate in the UBS Global Life
Sciences Conference on Wednesday, September 22, 2010, in New York.
Gary Ellis, senior vice president and chief financial officer of
Medtronic, will speak to attendees of the conference at 12:30 p.m. EDT
(11:30 a.m. CDT). Ellis will provide remarks highlighting Medtronic's
pl... |
| | | 09/13/10 | Medtronic Continues Membership in the Dow Jones Sustainability Index
and FTSE4Good Index| Medical Device Leader Recognized for Corporate Sustainability
MINNEAPOLIS, Sep 13, 2010 (BUSINESS WIRE) --Recognizing its leadership in meeting the needs of economic,
environmental, and social stakeholders, Medtronic, Inc. (NYSE: MDT) has
been named a member company in the North America Dow Jones
Sustainability Index (DJSI) and the FTSE4Good Index Series.
"We are honored by our continued inclusion in the DJSI and FTSE4Good
Indices," said Bill Hawkins, Medt... |
| | | 09/13/10 | Medtronic Introduces New CareLink(R) Remote
Monitoring Network for Heart Failure Clinicians| System Supports Proactive Patient Care for Patients at Risk for
Worsening Heart Failure
MINNEAPOLIS, Sep 13, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today introduced the CareLink(R)
Network for Heart Failure, an extension of the world's largest remote
implantable cardiac device monitoring system, that will be available
this fall for heart failure clinicians.
The patient management solution provides heart failure physicians and
nurses wit... |
| | | 09/10/10 | Medtronic Releases 2010 Corporate Citizenship Report| "Innovating for a Better World" Reviews Company's Economic, Social
and Environmental Performance for Fiscal Year 2010
MINNEAPOLIS, Sep 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) has released "Innovating for a Better World,"
the company's 2010 Corporate Citizenship Report. The online report,
which references Global Reporting Initiative (GRI) G3 Sustainability
Reporting Guidelines, is available at www.medtronic.com/2010CitizenshipReport
and pro... |
| | | 09/07/10 | Medtronic Gains CE Mark for Enhanced CoreValve(R) Delivery Catheter
System with AccuTrak Stability Layer| Innovative Technology Advances Greater Ease of Use Advantage for
Physicians During CoreValve Transcatheter Valve Implantation
MINNEAPOLIS, Sep 07, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced CE (Conformité Européenne)
Mark approval and the first global use and launch of the Medtronic
CoreValve(R) delivery system with AccuTrak(TM) Stability Layer for
transcatheter aortic valve implantation (TAVI). AccuTrak's proprietary
technology ... |
| | | 09/07/10 | Medtronic Announces First European Implant of New Drug-eluting Stent at Southampton General Hospital, UK| WATFORD, England, September 7, 2010 /PRNewswire via COMTEX/ --Resolute Integrity Stent Launched in the UK
Medtronic, Inc. (NYSE: MDT), announces the CE (Conformite Europeene) mark
and international launch of the Resolute Integrity Stent System for the
treatment of coronary artery disease, a leading cause of death and poor
quality of life.
Now available in the UK, and implanted for the first time in Europe at
Southampton General Hospital, the Resolute Integrity Stent System features a... |
| | | 09/03/10 | Medtronic CEO William Hawkins to Speak at Morgan Stanley Global
Healthcare Conference| MINNEAPOLIS, Sep 03, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology
company, today announced it will participate in the Morgan Stanley
Global Healthcare Conference on Monday, September 13, 2010, in New York
City.
William Hawkins, chairman and chief executive officer of Medtronic, is
scheduled to speak to attendees of the conference at 10:55 a.m. EDT
(9:55 a.m. CDT). Hawkins is scheduled to provide remarks hi... |
| | | 08/26/10 | Medtronic Receives Health Canada Approval for the Newest
Radiofrequency Ablation Tools for Atrial Fibrillation| Medtronic Ablation Frontiers Cardiac Ablation System Delivers
Treatment for the Most Common Heart Arrhythmia
MINNEAPOLIS & BRAMPTON, Ontario, Aug 26, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it received Health Canada
approval for the Medtronic Ablation Frontiers Cardiac Ablation System, a
novel radiofrequency (RF) ablation technology for the treatment of
atrial fibrillation (AF). AF is the most common heart arrhythmia that
... |
| | | 08/25/10 | Medtronic Response to Pakistan Flooding Relief Efforts| MINNEAPOLIS, Aug 25, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced today that it has pledged $100,000
through the Medtronic Foundation to support flooding relief efforts in
Pakistan.
The $100,000 will be directed to the American Refugee Committee (ARC) to
support mobile health teams working in the affected regions. Medtronic
employees worldwide also are offered five days of paid leave to assist
in relief efforts.
This donation is in ... |
| | | 08/25/10 | Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year
2011| MINNEAPOLIS, Aug 25, 2010 (BUSINESS WIRE) --The board of directors of Medtronic, Inc. (NYSE:MDT), today approved a
cash dividend of $0.225 per share of the company's common stock. The
dividend is payable on October 29, 2010, to shareholders of record at
the close of business on October 8, 2010.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
- alleviating pain, restoring he... |
| | | 08/24/10 | Medtronic Reports First Quarter Earnings| Updates Fiscal Year 2011 Revenue Outlook and EPS Guidance
MINNEAPOLIS, Aug 24, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced financial results for its
first quarter of fiscal year 2011, which ended July 30, 2010.
The company reported worldwide first quarter revenue of $3.773 billion,
compared to the $3.933 billion reported in the first quarter of fiscal
year 2010, a decrease of 4 percent as reported or an increase of 2
percent after adj... |
| | | 08/17/10 | Medtronic Signs Agreement to Acquire Osteotech| Acquisition Will Expand Product Offering, Pipeline and New Markets
for Biologics Business
MEMPHIS, Tenn., Aug 17, 2010 (BUSINESS WIRE) --Medtronic Inc., (NYSE: MDT) and Osteotech, Inc., (NASDAQ: OSTE) today
announced that the companies have signed a definitive agreement under
which Medtronic will acquire Osteotech for $6.50 per share in cash for
each share of Osteotech common stock. The total value of the transaction
is expected to be approximately $123... |
| | | 08/16/10 | Medtronic to Webcast Annual Shareholder Meeting| MINNEAPOLIS, Aug 16, 2010 (BUSINESS WIRE) --Medtronic investors and other interested parties are invited to
participate in a live Webcast of the Medtronic Annual Shareholder
Meeting on Wednesday, August 25, 2010, at 10:30 a.m. Central Time.
The webcast can be accessed by clicking on the Investor section link
through the Medtronic website at www.medtronic.com.
Within 24 hours of the webcast, a replay and a transcript of the
prepared remarks will be availabl... |
| | | 08/13/10 | Medtronic to Announce Financial Results for the First Quarter of Fiscal Year 2011| MINNEAPOLIS, Aug 13, 2010 (BUSINESS WIRE) --
Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the first quarter of its fiscal year 2011 on Tuesday, August 24, 2010. A news release will be issued at approximately 6:15 a.m. Central Time and will be available at http://www.medtronic.com/newsroom. The earnings news release will include summary financial information for Medtronic's first quarter ended July 30, 2010.
Medtronic will host a webcast at 7 a.m. Central... |
| | | 08/12/10 | Medtronic Completes Acquisition of ATS Medical| MINNEAPOLIS, Aug 12, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has completed its
acquisition of ATS Medical, Inc. following payment of $4.00 per share in
cash for each share of ATS Medical stock and assumption of net debt,
with a total transaction value of approximately $370 million.
"Medtronic is focused on providing innovative solutions for cardiac
surgeons and their patients worldwide," said John Liddicoat, M.D., vice
pr... |
| | | 08/06/10 | Medtronic Completes Enrollment in Clinical Study of Complete SE(R)
(Self-Expanding) Vascular Stent| Milestone Shows Progress on Indication-Specific Trials for Treating
Peripheral Arterial Disease
MINNEAPOLIS, Aug 06, 2010 (BUSINESS WIRE) --With an expanded focus on addressing peripheral arterial disease (PAD),
Medtronic, Inc. (NYSE: MDT), today announced that it has completed
enrollment in a clinical trial of the company's Complete SE
(self-expanding) vascular stent for the treatment of atherosclerosis in
the superficial femoral artery (SFA), includin... |
| | | 08/05/10 | First Patient Treated with Medtronic's Valiant(R)
Thoracic Stent Graft in Aortic Dissection Trial| Minimally Invasive Procedure May Stabilize Bleeding and Improve
Clinical Outcomes
MINNEAPOLIS, Aug 05, 2010 (BUSINESS WIRE) --Marking a major milestone toward expanding the use and utility of
minimally invasive endovascular procedures, Medtronic, Inc. (NYSE: MDT),
today announced the enrollment of the first patient in the Medtronic
Dissection Trial, which is evaluating the clinical performance of the
Valiant Thoracic Stent Graft with the Captivia Delive... |
| | | 07/29/10 | Medtronic Launches Novel Clinical Trial Evaluating Spinal Cord
Stimulation Therapy for Heart Failure| Defeat-HF Trial Aims to Slow HF Progression with Neurostimulation
MINNEAPOLIS, Jul 29, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the global launch of the
Defeat-HF (Determining the Feasibility of Spinal Cord Neuromodulation
for the Treatment of Chronic Heart Failure) clinical trial. It is the
industry's first prospective, randomized study evaluating the clinical
feasibility of spinal cord stimulation (SCS), or neurostimulation, to
... |
| | | 07/27/10 | Medtronic's AMPLIFY(TM) rhBMP-2 Matrix Receives Positive Votes from FDA
Advisory Panel on All Three Key Questions: Safety, Effectiveness and
Benefit/Risk| New biologic bone graft product demonstrated superior fusion rates
compared to current standard of care for complex fusion procedures of
the lower spine in the pivotal clinical trial
MINNEAPOLIS, Jul 27, 2010 (BUSINESS WIRE) --The U.S. Food and Drug Administration (FDA) Orthopaedic and
Rehabilitation Devices Panel today voted 9 for and 4 against (1
abstention) on safety and 10 for and 3 against (1 abstention) on
effectiveness, that data including result... |
| | | 07/26/10 | Study Shows Practice Improvement Program Enhances
Guideline-Recommended Device and Drug Therapy Use for Heart Failure
Patients| IMPROVE HFStudy Published in Circulation Demonstrates
Improved Adherence to Five of Seven Guideline-Recommended Care Measures
MINNEAPOLIS, Jul 26, 2010 (BUSINESS WIRE) --Results of the largest U.S. outpatient heart failure clinical study show
that implementation of a process improvement program significantly
improved adherence to evidence-based, guideline-recommended cardiac
resynchronization therapy (CRT), implantable cardioverter-defibrillator
(ICD) a... |
| | | 07/13/10 | Medtronic Partners with Patient Advocacy Groups to Launch Educational
Campaign to Raise Awareness of Spasticity| Release Your Potential Campaign Encourages People to Take Control of
Severe Spasticity and Seek Treatment
MINNEAPOLIS, Jul 13, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the launch of an educational
campaign, called Release Your PotentialSM,
that is designed to raise awareness of spasticity, a condition that
makes it difficult to voluntarily relax muscles.
Spasticity can result from brain injury, cerebral palsy, stroke,
mult... |
| | | 07/02/10 | Physio-Control Field Correction to LIFEPAK(R)
20/20e Defibrillator/ Monitors| MINNEAPOLIS, Jul 02, 2010 (BUSINESS WIRE) --Physio-Control, Inc., a wholly owned subsidiary of Medtronic, Inc.,
(NYSE: MDT), announced the company's recent initiation of a field
correction on certain LIFEPAK 20/20e defibrillator/monitors manufactured
prior to January 9, 2009. Analysis conducted by Physio-Control verified
a possible battery (DC) power malfunction on the affected devices. In
the malfunction scenario, a loss of battery power may occur while t... |
| | | 06/30/10 | Medtronic Receives CE Mark for Ensura MRI(TM) SureScan(TM) Pacing System
Approved for Use in MRI Machines as Labeled| New Option in Second-Generation Pacing System Available in Select
European Geographies Features Exclusive Technology and Allows Access to
Critical Diagnostic Tool
MINNEAPOLIS, Jun 30, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced today the company received CE
(Conformité Européenne) Mark for Ensura MRI(TM) SureScan(TM) pacing system.
Ensura MRI is the company's new option in the second-generation pacing
system, available in select Europea... |
| | | 06/29/10 | STAR 3 Trial Results Confirm Medtronic's Sensor-Augmented Insulin
Pump Therapy Achieves Better Glucose Control Than Daily Insulin
Injections in People with Diabetes| Results of Study Published in NEJM and Presented at ADA Could
Redefine the Standard of Care for People with Type 1 Diabetes
MINNEAPOLIS, Jun 29, 2010 (BUSINESS WIRE) --In the longest and largest randomized, controlled study of
sensor-augmented insulin pump therapy in type 1 diabetes, adult and
pediatric patients using the Medtronic MiniMed Paradigm(R) REAL-Time
System achieved better glucose control without an increase in
hypoglycemia compared to multip... |
| | | 06/25/10 | Medtronic Launches New Midas Rex(R) High-Speed Electric Drill for
Surgeons| New Surgical Drill Offers Power and Maneuverability with Easy
Fingertip Control
MINNEAPOLIS, Jun 25, 2010 (BUSINESS WIRE) --Medtronic, Inc.(NYSE: MDT) today announced availability of the
company's new Midas Rex(R) Legend(R) EHS Stylus Touch(TM)
high-speed electric drill for spinal, cranial and orthopaedic surgical
procedures. This is the first electric drill from Medtronic with
integrated finger control and is based on the well-established Legend
... |
| | | 06/25/10 | Medtronic Begins Enrollment in ASPIRE Pivotal Study of Low Glucose
Suspend Integrated System| Semi-Closed Loop System Designed to Reduce Severity and Duration of
Hypoglycemia
MINNEAPOLIS, Jun 25, 2010 (BUSINESS WIRE) --Demonstrating its dedication to close the loop for diabetes management,
Medtronic, Inc. (NYSE:MDT) today announced that the first patient has
been enrolled as part of the ASPIRE study of the MiniMed Paradigm x54
System featuring Low Glucose Suspend automation. Low Glucose Suspend
works by automatically suspending insulin delivery ... |
| | | 06/24/10 | Medtronic Increases Cash Dividend for First Quarter of Fiscal Year
2011| MINNEAPOLIS, Jun 24, 2010 (BUSINESS WIRE) --The board of directors of Medtronic, Inc. (NYSE:MDT), today approved a
cash dividend of $0.225 per share of the company's common stock; an
increase of 9 percent from the prior dividend paid to shareholders. The
dividend is payable on July 30, 2010, to shareholders of record at the
close of business on July 9, 2010.
"This dividend further demonstrates the board of directors' and
management's confidence in Medtr... |
| | | 06/23/10 | Medtronic Reiterates FY11 Guidance| MINNEAPOLIS, Jun 23, 2010 (BUSINESS WIRE) --Gary Ellis, senior vice-president and chief financial officer at
Medtronic, Inc. (NYSE: MDT) today reiterated fiscal year 2011 revenue
and diluted earnings per share (EPS) guidance at the Wells Fargo 2010
Healthcare Conference in Boston.
As previously disclosed, the company continues to expect fiscal year
2011 revenue growth in the range of 5 to 8 percent on a constant
currency basis. The company also continue... |
| | | 06/22/10 | Medtronic Announces 2010 ''Global Heroes''| Distance Runners from Around the World Who Benefit from Medical
Technology to Run this Fall in Medtronic Twin Cities Marathon Events
MINNEAPOLIS, Jun 22, 2010 (BUSINESS WIRE) --Twenty-five long-distance runners who benefit from medical technology
have been selected as 2010 Global Heroes by Twin Cities In Motion, the
non-profit organization that directs the Medtronic Twin Cities Marathon.
The honorees hail from Canada, Chile, China, Finland, Italy, Serbia,
... |
| | | 06/21/10 | Medtronic Launches Bone Cement with Hydroxyapatite in the United
States| KYPHON(R) ActivOs(TM)10 Bone Cement Is the Latest
Offering from Medtronic for Treatment of Vertebral Compression Fractures
MINNEAPOLIS, Jun 21, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced the launch of KYPHON ActivOs
10 Bone Cement with Hydroxyapatite, a polymethylmethacrylate (PMMA) bone
cement containing hydroxyapatite (HA) for use in the treatment of
patients with vertebral compression fractures (VCFs) who are undergoing
minimal... |
| | | 06/18/10 | Study: Medtronic Anatomically-Designed Catheters Reduce Lab Time
Required for Pulmonary Vein Isolation by 35 Percent| Data from FAST-PVI Study Presented at Cardiostim 2010
MINNEAPOLIS, & NICE, France, Jun 18, 2010 (BUSINESS WIRE) --Data from the FAST-PVI study, supported by Medtronic, Inc. (NYSE: MDT),
shows lab time using anatomically-designed ablation catheters are more
than one-third (35 percent) faster than traditional point-by-point focal
ablation procedures in achieving pulmonary vein isolation (PVI). PVI is
the cornerstone catheter procedure to treat paroxysmal atri... |
| | | 06/17/10 | Medtronic CFO Gary Ellis to Speak at the Wells Fargo Securities
Healthcare Conference| MINNEAPOLIS, Jun 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology
company, today announced it will participate in the Wells Fargo
Securities 2010 Healthcare Conference on Wednesday, June 23, 2010, in
Boston.
Gary Ellis, senior vice president and chief financial officer at
Medtronic, will speak to the attendees of the conference at 8 a.m.
Eastern time (7 a.m. Central). Mr. Ellis will provide remarks
h... |
| | | 06/17/10 | Medtronic Announces European Launch of Protecta(TM) Portfolio with
SmartShock(TM) Technology Shown to Significantly Reduce Inappropriate Shocks| New Data Released at Cardiostim 2010 Shows Benefits of Advanced Shock
Reduction Technologies
MINNEAPOLIS & NICE, France, Jun 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) today announced European launch of the
Protecta(TM)portfolio of implantable cardioverter-defibrillators
(ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds).
The implantable defibrillators feature Medtronic-exclusive SmartShock(TM)
Technology, comprised of s... |
| | | 06/10/10 | Medtronic CFO Gary Ellis to Speak at the William Blair Conference| MINNEAPOLIS, Jun 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology
company, today announced it will participate in the William Blair Growth
Stock Conference on Tuesday, June 15, 2010, in Chicago.
Gary Ellis, senior vice president and chief financial officer at
Medtronic, will speak to the attendees of the conference at 9:50 a.m.
Eastern time (8:50 a.m. Central). Mr. Ellis will provide remarks
highlighting Med... |
| | | 06/10/10 | Medtronic CEO William Hawkins to Speak at 31st Annual Goldman Sachs
Healthcare Conference| MINNEAPOLIS, Jun 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), the world's leading medical technology
company, today announced it will participate in the 31st
Annual Healthcare Conference on Tuesday, June 15, 2010, in Los Angeles.
William Hawkins, chairman and chief executive officer of Medtronic, will
speak to attendees of the conference at 2:30 p.m. Pacific time (4:30
p.m. Central). Hawkins will provide remarks highlighting Medtronic's
plan ... |
| | | 06/07/10 | Medtronic Launches Next-Generation Continuous Glucose Monitoring
System for Advanced Diabetes Management in 49 Countries around the World| iPro(TM)2 Professional CGM Provides Simple Way to Reveal
Insights Into Glucose Control Not Possible With Standard Glucose
Assessment Methods
MINNEAPOLIS, Jun 07, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT) announced today the launch of iPro(TM)2
Professional CGM, a continuous glucose monitoring (CGM) system used by
physicians to help improve diabetes management, in 49 countries around
the world. This simplified, yet more advanced fourth-generation... |
| | | 06/02/10 | New Data in the New England Journal of Medicine Show Medtronic
Deep Brain Stimulation Provides Sustained Motor Function Improvement in
Parkinson's Disease| MINNEAPOLIS, Jun 02, 2010 (BUSINESS WIRE) --In the largest, randomized, controlled study of deep brain stimulation
(DBS) for Parkinson's disease, Medtronic DBS Therapy was shown to
improve motor function for up to two years in patients with advanced
Parkinson's disease, showing equally strong efficacy for the two most
common surgical targets used for the therapy. The study, conducted at
seven Veterans Affairs and six university hospitals with participation... |
| | | 05/26/10 | Medtronic CoreValve(R) System Shows Long-Term
Efficacy and Durability in Pivotal Trial| Market-Leading Transcatheter Aortic Valve Delivers Positive Clinical
Outcomes Through Two Years in Major International Study; Achieves
10,000-patient Milestone
PARIS, May 26, 2010 (BUSINESS WIRE) --New clinical data presented today at EuroPCR demonstrate positive
long-term performance and durability for the CoreValve transcatheter
aortic valve replacement system from Medtronic, Inc. (NYSE: MDT).
Two-year results from the pivotal 18-French CoreValve mult... |
| | | 05/25/10 | Medtronic's Resolute(R) Drug-Eluting Stent
Matches Market-Leading Rival in Large Head-to-Head Study| One-Year Clinical Results from Innovative RESOLUTE All Comers Trial
Show Excellent Performance for Resolute DES in Challenging Patient
Population
PARIS, May 25, 2010 (BUSINESS WIRE) --The highly anticipated first results of the RESOLUTE All Comers study
were presented today during the late-breaking clinical trial session of
the 2010 EuroPCR meeting. In this novel 2,292-patient randomized trial,
the Resolute zotarolimus-eluting stent from Medtronic, Inc.... |
| | | 05/25/10 | Multiple European Clinical Registries Show Important Benefits of
Medtronic CoreValve(R) Transcatheter Aortic Valve
System| Data Demonstrates That Revolutionary Treatment for Patients with
Diseased Heart Valves Is Transitioning Successfully into Standard
Clinical Practice throughout Europe
PARIS, May 25, 2010 (BUSINESS WIRE) --New European data from five national clinical registries presented today
at EuroPCR report positive clinical outcomes for one of the most
exciting emerging therapies in cardiology - transcatheter aortic valve
implantation for treatment of severe aortic... |
| | | 05/25/10 | Record Fourth Quarter Caps Strong Year for Medtronic| International Revenue Growth of 20 Percent
MINNEAPOLIS, May 25, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT):
First $4 Billion Sales Quarter in Company History
Full Year Revenue of $15.8 Billion Increased 8 Percent
Full Year Non-GAAP Diluted EPS of $3.22 Grew 10%; GAAP Diluted EPS
of $2.79 Grew 52%
Fourth Quarter GAAP Cash Flow from Operations of $1.237 Billion
Medtronic, Inc. (NYSE: MDT) today announced financial results for its
four... |
| | | 05/20/10 | Cardiovascular Devices from Medtronic Featured Prominently at EuroPCR| Cardiology Meeting in Paris May 25-28 Includes New Data on Resolute(R)
Drug-Eluting Stent, IN.PACT Line of Drug-Eluting Balloons and CoreValve(R)
Transcatheter Aortic Valve
MINNEAPOLIS, May 20, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), announced today the schedule of important
clinical data presentations during EuroPCR, a major cardiology meeting
taking place May 25-28 in Paris at the Palais de Congrès.
The meeting will prominently feature several ... |
| | | 05/20/10 | Medtronic Announces 2010 Analyst Meeting and Webcast| Medtronic Institutional Investor and Analyst Meeting Scheduled for
Monday, June 7, 2010,
10 a.m. - 2:30 p.m. Eastern
MINNEAPOLIS, May 20, 2010 (BUSINESS WIRE) --Medtronic (NYSE: MDT) will host an institutional investor and analyst
meeting on Monday, June 7, 2010, in New York City from 10 a.m. - 2:30
p.m. Eastern Daylight Time. The meeting will include remarks from the
management team highlighting the company's strategy for delivering
sustainable top a... |
| | | 05/19/10 | First Patient Treated with Valiant(R) Thoracic
Stent Graft in Medtronic's ''RESCUE'' Clinical Study| Minimally-Invasive Procedure May Stabilize Aortic Bleeding When
Surgery Is Not an Option
MINNEAPOLIS, May 19, 2010 (BUSINESS WIRE) --Further demonstrating its commitment to proving the benefits of
minimally-invasive procedures, Medtronic, Inc. (NYSE: MDT), today
announced that the first patient has been treated with the company's
Valiant(R) Thoracic Stent Graft with the Captivia Delivery
System in Medtronic's RESCUE Clinical Study.
The RESCUE (Evalua... |
| | | 05/17/10 | Medtronic CFO Gary Ellis to Speak at the Citi Global Health Care
Conference| MINNEAPOLIS, May 17, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), today announced it will participate in the
2010 Citi Investment Research Global Health Care Conference on
Wednesday, May 26, 2010, in New York City.
Gary Ellis, senior vice president and chief financial officer at
Medtronic, will speak to the attendees of the conference at 2 p.m.
eastern time (1 p.m. central). Ellis will provide remarks highlighting
Medtronic's plan to deliver sust... |
| | | 05/15/10 | New Medtronic Data Shows Health Care Utilization Differs by Type of
Implantable Defibrillator Therapy| Studies Presented at Heart Rhythm 2010 Demonstrate Advantages of
Advanced Shock Reduction Technologies
MINNEAPOLIS & DENVER, May 15, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today released new data from the MVP
(Managed Ventricular Pacing) trial that implantable defibrillator
patients receiving anti-tachycardia pacing (ATP) were less likely to
have health care utilization after treatment as compared to those
receiving shock therapy. Only 2... |
| | | 05/14/10 | Medtronic Announces New Data from STOP AF Pivotal Trial| Trial Demonstrates Significant Decrease in Symptoms and Improved
Quality of Life for AF Patients Treated with Arctic Front(R)
Cardiac CryoAblation Catheter
MINNEAPOLIS & DENVER, May 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today released new STOP AF (Sustained
Treatment of Paroxysmal Atrial Fibrillation) clinical trial data showing
the number of paroxysmal atrial fibrillation (AF) patients reporting AF
symptoms declined by 80 percent... |
| | | 05/14/10 | Medtronic Announces Date for 2010 Annual Meeting| Shareholders Invited to Attend Annual Meeting on Aug. 25, 2010
MINNEAPOLIS, May 14, 2010 (BUSINESS WIRE) --The board of directors of Medtronic, Inc. (NYSE: MDT), today announced
that the company's annual meeting of shareholders will be held at 10:30
a.m., Central Daylight Time, on Wednesday, Aug. 25, 2010 at Medtronic
World Headquarters, located at 710 Medtronic Parkway, Minneapolis, Minn.
Shareholders of record at the close of business on June 28, 2010, will
... |
| | | 05/13/10 | Medtronic Data Show Effectiveness of Shock Reduction Technologies in
Further Reducing Inappropriate Shocks| Results of Virtual ICD Study Presented at Heart Rhythm 2010
MINNEAPOLIS & DENVER, May 13, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) released the Virtual ICD study data today
that predicted 98 percent of studied implantable defibrillator patients
would be free of inappropriate shocks one year after implant and 92
percent at five years post-implant. The Virtual ICD study used a
statistical model that predicts that six advanced shock-reduction
... |
| | | 05/13/10 | Late Breaking Clinical Trial Validates Value of Shock Reduction
Strategies| New Medtronic Evidence on Shock Reduction Device Programming
Strategies Released At Heart Rhythm 2010
MINNEAPOLIS & DENVER, May 13, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today released new evidence demonstrating
that key shock-reduction programming strategies significantly reduced
implantable cardioverter-defibrillator (ICD) and cardiac
resynchronization therapy defibrillator (CRT-D) shocks from 17 to 28
percent. The study also identifi... |
| | | 05/12/10 | Medtronic to Announce Financial Results for Its Fourth Quarter and
Fiscal Year Ended April 30, 2010| Webcast Scheduled for 7 a.m. CDT, May 25, 2010
MINNEAPOLIS, May 12, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced today it will report financial
results for its fourth quarter and fiscal year on Tuesday, May 25, 2010.
A news release will be issued at approximately 6:15 a.m. Central
Daylight Time and will be available at www.medtronic.com/newsroom.
The earnings news release will include summary financial information for
Medtronic's fourth ... |
| | | 05/10/10 | Medtronic Launches New Cellular Accessory for the Medtronic CareLink(R)
Network| New Option to Connect Patients and Clinics Underscores Medtronic's
Ongoing Efforts to Improve Clinic Efficiency and Simplify Patient
Follow-up
MINNEAPOLIS, May 10, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) announced today that it now offers the new
Medtronic M-Link(TM) cellular accessory, which provides cardiac device
patients with an option to securely send information stored in their
implanted devices to their clinics via the CareLink(R) Netw... |
| | | 05/06/10 | Medtronic Announces Clinical Trial for Breakthrough Technology in
Neurostimulation Therapy for Intractable Chronic Pain| RestoreSensor Neurostimulator Designed to Optimize Pain Relief for
Patients Regardless of Body Position
MINNEAPOLIS, May 06, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced the initiation of a
prospective, multi-center, randomized U.S. clinical trial for the
RestoreSensorTM neurostimulator that adapts therapy to the
changing needs of chronic pain patients by responding automatically to
changes in body position and activity in an uprig... |
| | | 05/03/10 | Medtronic Achieves Enrollment Milestone in 'CURE-AF'| Clinical Trial of Surgical Tissue Ablation Includes Two U.S. IDE
Studies
MINNEAPOLIS, May 03, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT), today announced completion of patient
enrollment in the first of two studies in the company's CURE-AF (Concomitant
Utilization of Radiofrequency
Energy for Atrial
Fibrillation) clinical
trial.
The trial consists of two U.S. investigational device exemption (IDE)
studies evaluating the safety... |
| | | 04/29/10 | Medtronic Signs Agreement to Acquire ATS Medical| Acquisition Will Expand Access to Innovative Treatment Options for
Structural Heart Disease
MINNEAPOLIS, Apr 29, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT), and ATS Medical, Inc. (NASDAQ:ATSI), today
announced that the companies have signed a definitive agreement under
which Medtronic will acquire ATS Medical by paying $4.00 per share in
cash for each share of ATS Medical stock. The total value of the
transaction is expected to be approximately $... |
| | | 04/27/10 | Physio-Control Launches Version 4.1 of Its LIFENET(R)
System| First-To-Market Feature Allows Integration of Data from Multiple
Vendors' 12-lead Management Systems
REDMOND, Wash., Apr 27, 2010 (BUSINESS WIRE) --Physio-Control, Inc., a wholly-owned subsidiary of Medtronic, Inc.,
(NYSE: MDT), today announced the launch of Version 4.1 of its LIFENET
System. LIFENET System 4.1 is a web-based platform designed to share
emergent patient information between Emergency Medical Services (EMS)
and hospital care teams. The lat... |
| | | 04/22/10 | Physio-Control Launches Voluntary Field Correction to a Limited
Number of LIFEPAK(R) 15 Monitor/Defibrillators| MINNEAPOLIS, Apr 22, 2010 (BUSINESS WIRE) --Physio-Control, Inc., a wholly-owned subsidiary of Medtronic, Inc.,
(NYSE: MDT), announced today the U.S. Food and Drug Administration (FDA)
has classified the company's decision to perform a voluntary correction
of LIFEPAK 15 monitor/defibrillators manufactured prior to December 16,
2009 as a Class I recall. Analysis conducted by Physio-Control verified
the affected devices were manufactured with an internal com... |
| | | 04/21/10 | Medtronic Receives FDA Approval for New Indication for Complete(R)
SE Vascular Stent| Now Indicated for Treatment of Peripheral Disease in the Iliac
Arteries, Self-Expanding (SE) Device Redefines Deployment Accuracy for
Precise Placement
MINNEAPOLIS, Apr 21, 2010 (BUSINESS WIRE) --Broadening the scope of innovation for cardiovascular interventions
beyond the heart, Medtronic, Inc. (NYSE: MDT), announced today that it
has received approval from the U.S. Food and Drug Administration (FDA)
for the Complete(R) SE Vascular Stent System to be ... |
| | | 04/21/10 | Medtronic Completes Acquisition of Invatec and Affiliated Companies| Acquisition Expands Product Offering and Pipeline for Cardiovascular
Interventions
MINNEAPOLIS, Apr 21, 2010 (BUSINESS WIRE) --Moving to expand its product offering,Medtronic, Inc. (NYSE:
MDT), announced today that it has completed the acquisition of Invatec,
a developer of innovative medical technologies for the interventional
treatment of cardiovascular disease. The acquisition includes two
affiliated companies: Fogazzi, which provides proprietary pol... |
| | | 04/14/10 | Medtronic Names Caroline Stockdale as Senior Vice President of Human
Resources| MINNEAPOLIS, Apr 14, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) today announced it has named Caroline
Stockdale as senior vice president of human resources effective April
30, 2010. In her role, Ms. Stockdale will report to Medtronic Chairman
and CEO, William A. Hawkins.
Ms. Stockdale will be responsible for the company's worldwide human
resources function including: global talent initiatives, leadership
development, diversity and inclusion, and... |
| | | 04/09/10 | Medtronic Hydrodebrider(TM) System Wins Medical Device Excellence Award| Hydrodebrider System Offers Innovative Treatment for Chronic Sinusitis
MINNEAPOLIS, Apr 09, 2010 (BUSINESS WIRE) --Medtronic (NYSE: MDT) announced today that the company was named a 2010
Medical Device Excellence Award (MDEA) winner for excellence in medical
device design for its Hydrodebrider(TM)
System, manufactured by the company's Ear Nose and Throat (ENT)
business unit. The Hydrodebrider System is the first and only powered
endoscopic irrigation sy... |
| | | 04/08/10 | Medtronic Receives 2010 Beacon Council Award for Outstanding
Contributions in Life Sciences| MINNEAPOLIS, Apr 08, 2010 (BUSINESS WIRE) --Medtronic, Inc., (NYSE:MDT) received yesterday a Beacon Award from The
Beacon Council, Miami-Dade County's official economic development
organization, in recognition for its outstanding contributions to the
Miami-Dade economy in the areas of job creation, business expansion,
corporate citizenship, and leadership in the Life Sciences Industry
category.
The Beacon Awards were presented to one company in various ... |
| | | 04/07/10 | Medtronic Launches New Frontal Handpiece for Its Hydrodebrider(TM) System| Hydrodebrider System Offers Innovative Treatment for Chronic
Sinusitis that Affects Nearly 30 Million US Adults1
MINNEAPOLIS, Apr 07, 2010 (BUSINESS WIRE) --Medtronic (NYSE: MDT) announced today the launch of a new Frontal
Handpiece for its Hydrodebrider(TM)
System, manufactured by the company's Ear Nose and Throat (ENT)
division. The Hydrodebrider System is the first and only powered
endoscopic irrigation system for removing bacteria from the paranasal... |
| | | 04/01/10 | Medtronic to Appeal Jury Verdict in U.S. Patent Case Involving
CoreValve(R) Transcatheter Aortic Valve System| MINNEAPOLIS, Apr 01, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT), announced today that it will appeal the
$73.5 million jury verdict returned in the U.S. District Court in
Delaware deciding that the CoreValve(R) transcatheter aortic valve system
infringes a valid U.S. Andersen patent owned by Edwards Lifesciences.
This jury verdict has no bearing on Medtronic's ability to sell
CoreValve products internationally or to conduct clinical trials in the
... |
| | | 04/01/10 | Medtronic Commends U.S. Congress and President for Including National
Pain Care Policy Act in Healthcare Reform Legislation to Address
Barriers to and Solutions for Effective Pain Management| Company Teams with Physician and Patient Communities to Pass the
National Pain Care Policy Act of 2009
MINNEAPOLIS, Apr 01, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE: MDT) commended the U.S. Congress and President
for signing H.R. 3590, the Patient Protection and Affordable Care Act
legislation that includes provisions of the National Pain Care Policy
Act of 2009. Medtronic worked closely with physician and the patient
community to support this impor... |
| | | 03/29/10 | Newly Published Data Show Medtronic InterStim(R)
Therapy Decreases Episodes of Chronic Fecal Incontinence and Positively
Impacts Quality of Life| InterStim Therapy for Bowel Control Currently Under Review by the
U.S. FDA
MINNEAPOLIS, Mar 29, 2010 (BUSINESS WIRE) --Data published in the March issue of the Annals of Surgery show
that investigational use of sacral nerve stimulation with Medtronic
InterStim(R) Therapy reduces fecal incontinent episodes
and increases quality of life in patients with the condition. The
120-patient, multi-center study - the largest trial of its kind in the
world... |
| | | 03/29/10 | Medtronic and AGA Medical Settle Patent Dispute| MINNEAPOLIS, Mar 29, 2010 (BUSINESS WIRE) --Medtronic, Inc. (NYSE:MDT), today announced the settlement of a lawsuit
it initiated against AGA Medical Corp. in 2007 for infringement of
Medtronic's Jervis patent family.
Under the terms of the settlement, in consideration of AGA's payments to
settle the litigation, Medtronic and AGA will end the litigation and
Medtronic will grant a non-exclusive license to AGA to use the Jervis
patent family.
Patents in... |
| | | 03/23/10 | First European Patients Enrolled in Largest Ever Randomised Controlled Trial of ITB Therapy(R) in Post-Stroke Patients With Severe Spasticity| TOLOCHENAZ, Switzerland, March 23, 2010 /PRNewswire via COMTEX/ -- Spasticity Affects a Significant Number of Post-Stroke Patients,
[1],[2],[3] and Many are not Adequately Treated by Standard Therapy [4]
Medtronic, Inc. (NYSE: MDT) today announced the enrollment of the first
European patients in the largest randomized controlled trial to date to
investigate the benefits of ITB Therapy(R) (Intrathecal Baclofen) in
post-stroke patients affected by spasticity. The announcement comes as the
Wo... |
| | | 03/19/10 | Medtronic Receives FDA Panel's Unanimous Recommendation for Approval
of Revo MRI(TM) SureScan(TM) Pacing System| Positive Step Toward the First Pacemaker System Approval in the United States for Use in the MRI EnvironmentMINNEAPOLIS, Mar 19, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced that the U.S. Food and Drug
Administration (FDA) Circulatory System Devices Panel of the Medical
Devices Advisory Committee has voted unanimously in favor of approval
with conditions of the Revo MRI(TM) SureScan(TM) pacing system designed as MR
Conditional, or safe for us... |
| | | 03/18/10 | First Publication of Data from Pivotal Clinical Trial for Medtronic
Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia| MINNEAPOLIS, Mar 18, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced that a landmark publication
highlighting results from the pivotal study for Medtronic Deep Brain
Stimulation (DBS) Therapy for epilepsy, known as SANTE(R) (Stimulation of
the Anterior Nucleus of the Thalamus in Epilepsy), was published online
today in the medical journal, Epilepsia. The SANTE study,
sponsored by Medtronic, is the largest and most rigorous clinical study... |
| | | 03/17/10 | Medtronic Completes Pre-Market Approval Submission to FDA for Arctic
Front(R) Cardiac CryoAblation Catheter System| MINNEAPOLIS, Mar 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has completed Pre-Market
Approval (PMA) submission in consideration for U.S. Food and Drug
Administration (FDA) approval for the Medtronic Arctic Front(R)
Cardiac CryoAblation Catheter System, which is designed for patients
with paroxysmal atrial fibrillation (PAF), an irregular quivering of the
upper chambers of the heart that starts and stops on its own. Atrial
... |
| | | 03/17/10 | Medtronic Announces Next-Generation Pacing System for Use in MRI
Machines Now Commercially Available in Selected European Geographies| Advisa DR MRI(TM) SureScan(TM) Represents the Most Advanced Pacing System from Medtronic that Combines MRI Compatibility with Exclusive Pacing TechnologyMINNEAPOLIS, Mar 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today the commercial availability
of the Advisa DR MRI(TM) SureScan(TM) pacemaker in selected European
geographies. The Advisa DR MRI SureScan pacemaker is the company's
second-generation pacemaker in a portfolio of devices from Medtronic
... |
| | | 03/17/10 | Medtronic Receives FDA Approval for Industry's Most Advanced
Integrated System for Diabetes Management| Next Generation Integrated System - MiniMed Paradigm(R) REAL-Time Revel(TM) System - Incorporates Predictive Alerts to Help Patients More Tightly Control DiabetesMINNEAPOLIS, Mar 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced it has received U.S. Food and
Drug Administration (FDA) approval for the MiniMed Paradigm(R) REAL-Time
Revel(TM) System, the next generation of the industry's only integrated
diabetes management system (insulin pump therapy, c... |
| | | 03/16/10 | Medtronic Introduces "Every Patient First" Initiative to Address
Disparities in Access to Health Care| Partnerships with American College of Cardiology and Association of Black Cardiologists and Latest Data from IMPROVE HF Clinical Study All Aim to Drive Equitable TreatmentMINNEAPOLIS & ATLANTA, Mar 16, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today introduced Every Patient First, a
health equity initiative that, in partnership with health care
providers, professional societies and patient advocacy groups, aims to
reduce disparities in access to health care ... |
| | | 03/15/10 | Medtronic Announces Initial Results of STOP AF Clinical Trial| Safety and Effectiveness Trial Evaluated the Arctic Front(R) Cardiac CryoAblation Catheter System for the Treatment of Paroxysmal Atrial FibrillationMINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced data from the STOP AF
(Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial
during late-breaking sessions at the 59th Annual Scientific
Session of the American College of Cardiology in Atlanta. The data
... |
| | | 03/15/10 | Medtronic CareLink(R) Network Remote
Monitoring Significantly Reduced Time to Clinical Decision| Late Breaking Clinical Trial at 59th Annual Scientific Session of the American College of Cardiology (ACC) also Showed Shortened Cardiovascular Hospital StaysMINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced results from the CONNECT
trial showing the median time to clinical decision was significantly
reduced for cardiac resynchronization therapy-defibrillator (CRT-D) and
implantable cardioverter-defibrillator (ICD) pati... |
| | | 03/14/10 | Medtronic's Endeavor Stent Continues to Demonstrate Compelling and
Consistent Long-Term Clinical Results| Independent Analysis of Large and Comprehensive ENDEAVOR Program Shows Remarkably Durable Safety and Efficacy at Five Years of Follow Up in Coronary Artery Disease PatientsMINNEAPOLIS & ALTANTA, Mar 14, 2010 (BUSINESS WIRE) -- The consistency and quality of the long-term clinical results for the
Endeavor(R) drug-eluting stent (DES) from Medtronic, Inc.
(NYSE: MDT), continue to distinguish it as a treatment for coronary
artery disease, according to newly released data.... |
| | | 03/12/10 | FDA Panel Recommends Approval with Conditions of Medtronic Deep Brain
Stimulation Therapy for Patients with Refractory Epilepsy| MINNEAPOLIS, Mar 12, 2010 (BUSINESS WIRE) -- The U.S. Food and Drug Administration (FDA) Neurological Devices Panel
today voted seven to five to recommend approval with conditions of Deep
Brain Stimulation (DBS) Therapy for Epilepsy from Medtronic, Inc. (NYSE:
MDT) as adjunctive treatment for partial-onset seizures in adults with
medically refractory epilepsy. If the FDA follows the recommendation of
the panel, the therapy will be approved for the treatmen... |
| | | 03/12/10 | Medtronic Starts International Study of CoreValve(R) Transcatheter Aortic Valve System| Post-Market Evaluation of Breakthrough Medical Device Begins Enrolling Patients; First Implants Occur in GermanyMINNEAPOLIS, Mar 12, 2010 (BUSINESS WIRE) -- Moving to expand the evidence base for the future of structural heart disease therapy,Medtronic, Inc. (NYSE: MDT), today announced the start of the first of several new initiatives in a robust international clinical program for its CoreValve transcatheter aortic valve system, a minimally-invasive alternative to open-heart surgery for aortic ... |
| | | 03/11/10 | Medtronic Announces Public Offering of Senior Notes| MINNEAPOLIS, Mar 11, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced a registered offering of
$1.25 billion of its 3.0 percent Senior Notes due 2015, $1.25 billion of
its 4.45 percent Senior Notes due 2020 and $500 million of its 5.55
percent Senior Notes due 2040 (collectively, the "Notes"). Medtronic
intends to use the net proceeds for working capital and general
corporate purposes, which may include the repayment of its indebtedness.
... |
| | | 03/10/10 | Medtronic Introduces the VERTEX SELECT(R) Reconstruction
System| Offering Surgeons the Next Generation of Occipitocervical Upper-Thoracic FixationMEMPHIS, Tenn., Mar 10, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced the U.S. launch of the
VERTEX SELECT(R) Reconstruction System.
When a patient has a spinal condition that requires fusion or a
procedure that must be performed from the back of the spine, also known
as a posterior approach, the VERTEX SELECT(R) Reconstruction
System contains implants and an in... |
| | | 03/09/10 | William A. Hawkins, Medtronic Chairman and CEO, Receives
Distinguished Achievement Award from Biomedical Engineering Society| Lecture Published by Annals of Biomedical EngineeringMINNEAPOLIS, Mar 09, 2010 (BUSINESS WIRE) -- Medtronic, Inc., (NYSE: MDT), today announced William A. Hawkins,
chairman and CEO, recently received the Biomedical Engineering Society's
Distinguished Achievement Award. As part of the award, the plenary
lecture he delivered to the organization was published in the March 2010
edition of the Annals of Biomedical Engineering. The
Distinguished Achievement Awar... |
| | | 03/03/10 | Medtronic Recognized for Excellence in Corporate Citizenship| Corporate Responsibility Magazine lists Medtronic among 2010's 100 Best Corporate CitizensNEW YORK, Mar 03, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) was named today to the 11th
annual "100 Best Corporate Citizens List" published by Corporate
Responsibility magazine (formerly known as CRO magazine).
Ranking 77th, this is the first time Medtronic has appeared on the list,
which is recognized as one of the nation's top corporate responsibility
rank... |
| | | 03/03/10 | Medtronic Named Among World's Most Innovative Companies by MIT Technology
Review| MINNEAPOLIS, March 4, 2010 /PRNewswire via COMTEX/ -- Company Recognized for Ground-Breaking Work in the Field of Deep Brain
Stimulation
Medtronic, Inc. (NYSE: MDT) today announced that it has been selected as
one of Massachusetts Institute of Technology (MIT) Technology Review's 50
most innovative companies. Known as TR50, the first annual list includes
companies that Technology Review believes have demonstrated superiority in
inventing technology and in using it both to grow their own bu... |
| | | 03/02/10 | Medtronic CFO Gary Ellis to Speak at the Cowen & Company Health Care
Conference| MINNEAPOLIS, Mar 02, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced it will participate in the
30th Annual Cowen and Company Health Care Conference on
Tuesday, March 9, 2010, in Boston, MA.
Gary Ellis, senior vice president and chief financial officer at
Medtronic, will speak to the attendees of the conference at 3:45 p.m.
eastern time (2:45 p.m. central). Mr. Ellis will provide remarks
highlighting Medtronic's plan to deliver sustai... |
| | | 02/24/10 | Medtronic Chairman and CEO Bill Hawkins Elected American Institute of
Medical and Biological Engineering Fellow| MINNEAPOLIS, Feb 24, 2010 (BUSINESS WIRE) -- Medtronic, Inc., (NYSE: MDT), today announced William A. Hawkins,
chairman and CEO, has been elected a Fellow of the American Institute of
Medical and Biological Engineering (AIMBE). AIMBE Fellows are recognized
for their outstanding achievements in medical and biological
engineering. A formal induction ceremony was held at the Institute's 19th
Annual Event in Washington, D.C., Feb. 21-23, 2010.
In addition to ... |
| | | 02/23/10 | Medtronic Third Quarter Revenue Increases 10% to $3.851 Billion;
Raises Lower End of EPS Guidance for Current Fiscal Year| Non-GAAP diluted EPS of $0.77 grew 8%; GAAP diluted EPS of $0.75 grew 21%International revenue of $1.615 billion grew 11% on a constant currency basis; 22% as reportedFree cash flow exceeds $1.3 billion; GAAP cash flow from operations of $1.488 billionWorldwide ICD revenue growth of 5% on a constant currency basis; 9% as reportedWorldwide CardioVascular revenue growth of 21% on a constant currency basis; 28% as reportedMINNEAPOLIS, Feb 23, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today... |
| | | 02/19/10 | Physio-Control Resumes Unrestricted Global Shipments of Its LIFEPAK(R)
Defibrillators| REDMOND, Wash., Feb 19, 2010 (BUSINESS WIRE) -- Physio-Control Inc., a wholly-owned subsidiary of Medtronic, Inc. (NYSE:
MDT), announced today it received notice from the U.S. Food and Drug
Administration (FDA) that having successfully met requirements
for improvements to the quality system, the company may resume
unrestricted worldwide shipments of its external defibrillators.
In May 2008, Physio-Control signed a Consent Decree with the FDA to
address is... |
| | | 02/18/10 | Medtronic Board Approves Fourth Quarter Cash Dividend for Fiscal Year 2010| MINNEAPOLIS, Feb 18, 2010 (BUSINESS WIRE) -- The board of directors of Medtronic, Inc. (NYSE:MDT), today approved a
cash dividend of $0.205 per share of the company's common stock. The
dividend is payable on April 30, 2010, to shareholders of record at the
close of business on April 9, 2010.
About Medtronic
Medtronic, Inc. (www.medtronic.com),
headquartered in Minneapolis, is the global leader in medical technology
- alleviating pain, restoring health, a... |
| | | 02/17/10 | Rebecca Bergman Elected to National Academy of Engineering| Medtronic Vice President Becomes Part of Elite Group of EngineersMINNEAPOLIS, Feb 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that Rebecca Bergman, vice
president of new therapies and diagnostics in the Cardiac Rhythm Disease
Management (CRDM) business, was elected to the National Academy of
Engineering (NAE). The NAE now has 2,267 peer-elected members in the
United States and an additional 196 foreign associates. They provide the
... |
| | | 02/11/10 | German Appeals Court Says CoreValve Devices From Medtronic Do Not
Infringe Edwards Lifesciences' Andersen Patent| Consistent With Lower Court Ruling, Latest Legal Decision Enables Uninterrupted Access to Leading Transcatheter Heart Valve in GermanyMINNEAPOLIS, Feb 11, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today that an appeals court in
Germany has found that the CoreValve(R) transcatheter aortic
valve system does not infringe Edwards Lifesciences' German Andersen
patent, which is set to expire in May 2011. The appellate court's
decision upholds a lowe... |
| | | 02/10/10 | Medtronic to Announce Financial Results for Its Third Fiscal Quarter| Webcast Scheduled for 7 a.m. CST, February 23, 2010MINNEAPOLIS, Feb 10, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), announced today it will report financial
results for its third fiscal quarter on Tuesday, Feb. 23, 2010. A news
release will be issued at approximately 6:15 a.m. Central Time and will
be available at www.medtronic.com/newsroom.
The earnings news release will include summary financial information for
Medtronic's third quarter ended Ja... |
| | | 02/08/10 | Medtronic Donates Medical Supplies to Haiti Relief Effort| Company Response Surpasses $2.1 Millionfor Immediate and Long-Term Relief EffortsMINNEAPOLIS, Feb 08, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that the company has donated nearly $900,000 in medical devices and surgical supplies to help meet urgent medical needs in Haiti.
In response to numerous spine and crush injuries, the company provided spinal surgical implants such as rods, hooks and screws to treat spinal fractures, facilitate spinal fusion and stabilize and s... |
| | | 02/05/10 | Study Suggests Slide-On(R) EndoSheath(R) System Provides Several
Advantages over Traditional Germicidal Immersion| Study Presented at the Combined Sections Meetings of the Triological Society, the most prestigious society in Otolaryngology, received the John J. Conley Resident Research Award (Eastern Section)MINNEAPOLIS, Feb 05, 2010 (BUSINESS WIRE) -- Results of a clinical study presented Thursday, Feb. 4 at the annual
Triological Society meetings in Orlando, Fla., suggest a sterile barrier
sheath system has distinct advantages over germicidal immersion
processes used to prevent cont... |
| | | 01/28/10 | Medtronic Announces Two Late Breaking Clinical Trials Accepted for American College of Cardiology Meeting| First Release of STOP-AF Data on Medtronic Arctic Front(R) Cryoballoon for Paroxysmal Atrial Fibrillation PatientsMINNEAPOLIS, Jan 28, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today pivotal data for the Medtronic Arctic Front(R) CryoAblation Catheter System will be presented as a late breaking clinical trial at the 59th Annual Scientific Session of the American College of Cardiology on Monday, March 15 at 8 a.m. ET. The STOP-AF (Sustained Treatment of Paroxysmal Atrial Fibri... |
| | | 01/25/10 | Medtronic Receives FDA Approval for First Replacement Heart Valve Implanted without Surgery| Melody(R) Transcatheter Pulmonary Valve Offers Non-Surgical Valve Replacement Option for Congenital Heart Disease PatientsMINNEAPOLIS, Jan 25, 2010 (BUSINESS WIRE) -- In a significant development for congenital heart disease patients, Medtronic, Inc. (NYSE: MDT), announced today that its Melody(R) Transcatheter Pulmonary Valve has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first transcatheter heart ... |
| | | 01/25/10 | Medtronic to Acquire Invatec and Affiliated Companies| Acquisition Will Expand Product Offering and Pipeline for Cardiovascular InterventionsMINNEAPOLIS, Jan 25, 2010 (BUSINESS WIRE) -- Moving to expand its impact on peripheral vascular disease,Medtronic, Inc. (NYSE:MDT), announced today that it has signed a definitive agreement to acquire Invatec, a developer of innovative medical technologies for the interventional treatment of cardiovascular disease, and two affiliated companies: Fogazzi, which provides polymer technology to Invatec; and Krauth C... |
| | | 01/21/10 | Medtronic Pledges $1 Million to Haiti Earthquake Relief| Funding provided for immediate and long-term relief effortsMINNEAPOLIS, Jan 21, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) announced today that it has pledged $1 million through the Medtronic Foundation to support earthquake relief efforts in Haiti. Contributions could exceed $1.25 million with product and employee donations.
The Foundation will match employee donations up to $250,000, with matching funds directed to Partners in Health. An additional $750,000 in grants will be directe... |
| | | 01/19/10 | Medtronic Seeking Long-Distance Runners Who Benefit from Medical Technology| "Global Heroes" Will Receive Entry and Travel to the Medtronic Twin Cities Marathon or Medtronic TC 10 Mile in OctoberMINNEAPOLIS, Jan 19, 2010 (BUSINESS WIRE) -- Medtronic (NYSE: MDT) announced today it is recruiting runners from around the world who benefit from medical technology to participate in the fifth annual Medtronic Global Heroes program. Up to 25 runners will be selected to receive a paid entry for themselves and a guest to the Medtronic Twin Cities Marathon or the Medtronic TC 10 Mi... |
| | | 01/04/10 | Medtronic CEO William Hawkins to Speak at 28th Annual J.P. Morgan Healthcare Conference| MINNEAPOLIS, Jan 04, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT), today announced it will participate in the 28th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 11, 2010, in San Francisco.
William Hawkins, chairman and chief executive officer of Medtronic, will speak to attendees of the conference at 10 a.m. pacific time (12 p.m. central time). Hawkins will provide remarks highlighting Medtronic's plan to deliver sustainable top and bottom line growth. A live audio webcast of... |
| |
|
